AngioDynamics revenue rises 8% as NanoKnife sales surge

• AngioDynamics reported fourth-quarter revenue of $86.6 million, up 8% from the previous year.
• NanoKnife sales increased 64.5%, while total Med Tech revenue grew 16.7% to $41.8 million.
• The company forecast fiscal 2027 revenue of $336 million–$341 million and Med Tech growth of 12%–15%.

AngioDynamics (NASDAQ:ANGO) reported fiscal fourth-quarter revenue of $86.6 million, up 8%, as Med Tech growth offset a wider $11.4 million GAAP net loss.

Med Tech revenue increased 16.7% to $41.8 million, led by NanoKnife’s 64.5% growth and Auryon’s 14.4% increase, while Med Device sales rose 1.1% to $44.8 million.

The company reported a $0.27 GAAP loss per share, a $0.07 adjusted loss per share, $3.3 million in adjusted EBITDA and $17.5 million in operating cash flow.

AngioDynamics forecast fiscal 2027 sales of $336 million–$341 million and adjusted EBITDA of $13 million–$16 million.

Meanwhile, full-year revenue increased 9.4% to $320.2 million, with Med Tech sales rising 18.4% to $150 million and adjusted EBITDA reaching $13.2 million.

AngioDynamics also secured Medicare coverage for eligible NanoKnife prostate and liver procedures, advanced several thrombectomy studies and ended fiscal 2026 with $53.9 million in cash and no debt.